Compare Ascendis Pharma A/S (ASND) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.8. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals.
| ASND | FLRN | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $30.86 |
52-Week Low | $163.32 | $30.65 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FLRN, the SPDR Bloomberg Investment Grade Floating Rate ETF, trades at $30.80, showing minimal daily movement. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights institutional buying interest amid a rising rate environment, positioning FLRN as a potential hedge against inflation. The ETF pays consistent dividends, with recent distributions of $0.11 per share.
FLRN's outlook is shaped by its role in a higher-for-longer rate climate, offering floating-rate bond exposure that may outperform traditional fixed-income ETFs. Key risks include interest rate volatility and inflation trends. Institutional accumulation signals confidence, but the bearish technical trend warrants caution for near-term price action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
